Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study
AuthorsDave, R. V.
Taxiarchi, V. P.
Kirkham, J. J.
Camacho, E. M.
Cartlidge, C. W. J.
McIntosh, S. A.
Leff, D. R.
Coles, C. E.
Cutress, R. I.
Kirwan, Cliona C
AffiliationThe Nightingale Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M23 9LT, UK
MetadataShow full item record
AbstractBackground: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated 'standard' or 'COVID-altered', in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had 'COVID-altered' management. 'Bridging' endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2-9%) using 'NHS Predict'. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of 'COVID-altered' management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.
CitationDave RV, Kim B, Courtney A, O'Connell R, Rattay T, Taxiarchi VP, et al. Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study. Br J Cancer. 2021.
JournalBritish Journal of Cancer
- GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain.
- Authors: Martin M, Guerrero-Zotano A, Montero Á, Jara C, Filipovich E, Rojo F, Moreno F, García-Sáenz JÁ, Alés JE, Chacón JI, Cruz J, Gimenez J, Cruz-Merino L, Algara M, Santisteban M, Tarruella SL, GEICAM Spanish Breast Cancer Group Steering Committee.
- Issue date: 2020 Sep
- Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review.
- Authors: Krishnaratne S, Pfadenhauer LM, Coenen M, Geffert K, Jung-Sievers C, Klinger C, Kratzer S, Littlecott H, Movsisyan A, Rabe JE, Rehfuess E, Sell K, Strahwald B, Stratil JM, Voss S, Wabnitz K, Burns J
- Issue date: 2020 Dec 17
- Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
- Authors: van Marcke C, Honoré N, van der Elst A, Beyaert S, Derouane F, Dumont C, Aboubakar Nana F, Baurain JF, Borbath I, Collard P, Cornélis F, De Cuyper A, Duhoux FP, Filleul B, Galot R, Gizzi M, Mazzeo F, Pieters T, Seront E, Sinapi I, Van den Eynde M, Whenham N, Yombi JC, Scohy A, van Maanen A, Machiels JP
- Issue date: 2021 May 20
- A prospective cohort study of the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland.
- Authors: Romics L, Doughty J, Stallard S, Mansell J, Blackhall V, Lannigan A, Elgammal S, Reid J, McGuigan MC, Savioli F, Tovey S, Murphy D, Reid I, Malyon A, McIlhenny J, Wilson C
- Issue date: 2021 Feb
- Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST).
- Authors: Gasparri ML, Gentilini OD, Lueftner D, Kuehn T, Kaidar-Person O, Poortmans P
- Issue date: 2020 Aug